Septra Ds

Shigellosis, Nocardiosis, Brucellosis + 12 more

Treatment

17 FDA approvals

18 Active Studies for Septra Ds

What is Septra Ds

Sulfamethoxazole

The Generic name of this drug

Treatment Summary

Sulfamethoxazole is an antibiotic that helps fight bacterial infections. It works by blocking the bacteria's ability to make folic acid, which is necessary for the bacteria to multiply and grow. Sulfamethoxazole is usually given in combination with trimethoprim, which blocks another step in the bacteria's folic acid production. This combination is used to treat infections of the urinary, respiratory, and gastrointestinal tracts.

Septra DS

is the brand name

image of different drug pills on a surface

Septra Ds Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Septra DS

Sulfamethoxazole

1973

278

Approved as Treatment by the FDA

Sulfamethoxazole, otherwise known as Septra DS, is approved by the FDA for 17 uses like Brucellosis and Pneumocystis Jirovecii Pneumonia .

Brucellosis

Used to treat Brucellosis in combination with Gentamicin

Pneumocystis Jirovecii Pneumonia

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Trimethoprim

Bronchitis

Used to treat Acute Exacerbation of Chronic Bronchitis (AECB) caused by susceptible bacteria in combination with Trimethoprim

Urinary tract infection

Used to treat Urinary Tract Infection caused by susceptible bacteria in combination with Trimethoprim

susceptible Enteritis infectious caused by Shigella sonnei

Used to treat susceptible Enteritis infectious caused by Shigella sonnei in combination with Trimethoprim

Diarrhea

Used to treat susceptible Travelers' Diarrhea caused by Enterotoxigenic E. Coli (ETEC) Infection in combination with Trimethoprim

Brucellosis

Used to treat Brucellosis in combination with Gentamicin

Shigellosis

Used to treat Dysentery, Bacillary in combination with Trimethoprim

Nocardiosis

Used to treat Nocardiosis in combination with Trimethoprim

susceptible Enteritis infectious caused by Shigella flexneri

Used to treat susceptible Enteritis infectious caused by Shigella flexneri in combination with Trimethoprim

Genus Pneumocystis

Used to treat risk of Pneumocystis jiroveci pneumonia (PCP) in combination with Trimethoprim

Otitis Media

Used to treat Acute Otitis Media caused by susceptible bacteria in combination with Trimethoprim

Pneumonia, Pneumocystis

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Trimethoprim

Immunocompromised

Used to treat Immunocompromised in combination with Trimethoprim

Electrolyte replacement

Used to treat Electrolyte replacement in combination with Trimethoprim

Fluid replacement therapy

Used to treat Fluid replacement therapy in combination with Trimethoprim

Cholera

Used to treat susceptible Cholera in combination with Trimethoprim

Effectiveness

How Septra Ds Affects Patients

Sulfamethoxazole is an antibiotic used to treat bacterial infections. It works by blocking a crucial step in bacterial growth. It is commonly paired with another drug called trimethoprim, which inhibits a different step in bacterial growth. Together, these drugs are better at slowing down bacterial resistance than either one alone. Sulfamethoxazole can cause allergic reactions, so if you experience a rash while taking this drug, you should stop immediately. It may also contribute to folate deficiency, so people at a higher risk of developing a deficiency should be cautious when taking this drug. People with glucose-6-phosph

How Septra Ds works in the body

Sulfamethoxazole works by stopping bacteria from being able to produce folic acid. Most bacteria get the folic acid they need by converting PABA into it, which Sulfamethoxazole prevents. This stops the bacteria from making purines and DNA, keeping it from multiplying and causing an infection.

When to interrupt dosage

The suggested dosage of Septra Ds is contingent upon the diagnosed condition, including Urinary tract infection, Pneumocystis Jirovecii Pneumonia and Fluid replacement therapy. The degree of dosage fluctuates as per the system of delivery featured in the table beneath.

Condition

Dosage

Administration

Shigellosis

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Immunocompromised

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Otitis Media

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Nocardiosis

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Brucellosis

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Electrolyte replacement

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Fluid replacement therapy

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Pneumonia, Pneumocystis

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Cholera

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Diarrhea

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Genus Pneumocystis

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Urinary tract infection

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Bronchitis

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

susceptible Enteritis infectious caused by Shigella sonnei

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

susceptible Enteritis infectious caused by Shigella flexneri

800.0 mg, , 400.0 mg, 200.0 mg/mL, 0.8 mg, 8.0 mg, 500.0 mg, 100.0 mg, 80.0 mg/mL, 200.0 mg, 40.0 mg/mL

Tablet - Oral, Tablet, Oral, , Suspension, Suspension - Oral, Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Solution - Intravenous, Solution, Injection, Injection - Intravenous

Warnings

Septra Ds Contraindications

Condition

Risk Level

Notes

Megaloblastic anemia caused by Folate deficiency

Do Not Combine

hepatic damage

Do Not Combine

Purpura, Thrombocytopenic, Idiopathic

Do Not Combine

Pulse Frequency

Do Not Combine

Disease

Do Not Combine

unable to monitor renal function

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Sulfamethoxazole may interact with Pulse Frequency

There are 20 known major drug interactions with Septra Ds.

Common Septra Ds Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Sulfamethoxazole.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Sulfamethoxazole.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Sulfamethoxazole.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Sulfamethoxazole.

Amiodarone

Major

The metabolism of Amiodarone can be decreased when combined with Sulfamethoxazole.

Septra Ds Toxicity & Overdose Risk

Sulfamethoxazole has a toxic dose of 2300 mg/kg in mice and 6200 mg/kg in rats. Symptoms of an overdose may include loss of appetite, stomach pain, nausea, vomiting, dizziness, headache, drowsiness, and passing out. In more severe cases, people may also experience fever, blood in urine, or kidney stones. Treatment for overdose includes treating the symptoms, inducing vomiting or using a stomach pump, and monitoring the patient’s blood work for signs of blood disorders or electrolyte imbalances.

image of a doctor in a lab doing drug, clinical research

Septra Ds Novel Uses: Which Conditions Have a Clinical Trial Featuring Septra Ds?

8 active clinical trials are currently being conducted to evaluate the potential of Septra DS in aiding Immunocompromised Patients, Fluid Replacement Therapy and treating susceptible Enteritis Infections caused by Shigella sonnei.

Condition

Clinical Trials

Trial Phases

Electrolyte replacement

0 Actively Recruiting

Nocardiosis

0 Actively Recruiting

Fluid replacement therapy

0 Actively Recruiting

Pneumonia, Pneumocystis

1 Actively Recruiting

Phase 3

susceptible Enteritis infectious caused by Shigella flexneri

0 Actively Recruiting

Brucellosis

0 Actively Recruiting

Genus Pneumocystis

0 Actively Recruiting

Diarrhea

14 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Early Phase 1

Otitis Media

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

Cholera

0 Actively Recruiting

Bronchitis

0 Actively Recruiting

Immunocompromised

3 Actively Recruiting

Not Applicable, Phase 1

susceptible Enteritis infectious caused by Shigella sonnei

0 Actively Recruiting

Shigellosis

0 Actively Recruiting

Septra Ds Reviews: What are patients saying about Septra Ds?

5

Patient Review

9/10/2018

Septra Ds for Urinary Tract Infection due to E. Coli Bacteria

So far, this medication has been working well for me. I experienced some leg cramps on the first night, but I think that was because I wasn't staying hydrated enough. But since then, no issues whatsoever and my UTI symptoms have vanished.

5

Patient Review

1/24/2016

Septra Ds for Skin Infection

I've had to take this medication a few times now, and it's always worked well in clearing up my skin infections. I haven't experienced any negative side effects, which is great.

4.7

Patient Review

11/11/2014

Septra Ds for Skin Infection

I've taken this medication multiple times to treat cystic acne, and it works great. I haven't had any significant side effects from it.

3

Patient Review

12/9/2013

Septra Ds for Skin Infection

I got an infection from a cyst on my leg, and this medication made me feel nauseous for three days. I was also itchy, tired, and overall felt worse than before I saw the doctor.

2.7

Patient Review

9/8/2014

Septra Ds for Bacterial Urinary Tract Infection

I was prescribed this medication for a week-long UTI, and within an hour of taking the pill I started feeling intense pain in my lips. They swelled up until they burst, and I was left with oozing inflammation for two weeks.

2.3

Patient Review

7/13/2013

Septra Ds for Skin Infection

Avoid this treatment at all costs.

1.7

Patient Review

9/30/2019

Septra Ds for Urinary Tract Infection due to E. Coli Bacteria

I was unfortunately one of the people who had a really negative reaction to this drug. I felt nauseous and sweaty, had a headache and pain in my back, and generally felt awful. My heart also started acting up, which was really scary. I would never recommend this to anyone.

1

Patient Review

3/25/2015

Septra Ds for Urinary Tract Infection Prevention

Unfortunately, I had a really negative reaction to this drug. I felt nauseous and threw up, and also had a headache.

1

Patient Review

7/25/2014

Septra Ds for Bacterial Urinary Tract Infection

I had a really negative reaction to this medication, including chills and difficulty breathing. The effects were so bad that I didn't even finish the course of pills.

1

Patient Review

7/16/2013

Septra Ds for Bacterial Urinary Tract Infection

I had a terrible reaction to this drug. I started experiencing diarrhea within two hours of taking the first pill. The next day, my fever was so high that I had to go to the emergency room and get a breathing treatment. After discontinuing the drug, I developed mouth sores around my lips.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about septra ds

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are Septra and Bactrim the same?

"Sulfamethoxazole and trimethoprim are medications that are used to treat bacterial infections. These two medications are usually given together in a combination antibiotic treatment. The combination of these antibiotics is used to treat a variety of infections, including urinary tract infections (UTIs)."

Answered by AI

What is Septra DS used for?

"The drug is effective in treating a variety of bacterial infections, including those in the middle ear, urine, respiratory system, and intestines. It can also be used to prevent and treat pneumonia caused by the pneumocystis virus."

Answered by AI

How long does it take for Septra DS to work?

"For more common problems such as urinary tract infections and ear infections, most people will start to feel relief after a few days. However, for more complicated problems such as pneumonia, it might take 2 to 3 weeks to feel improvement."

Answered by AI

What does DS stand for in septra DS?

"40, hypromellose, magnesium stearate, and polyethylene glycol.

Each SEPTRA DS tablet contains 160 mg trimethoprim, 800 mg sulfamethoxazole, 0.8 mg docusate sodium, FD&C Red No. 40, hypromellose, magnesium stearate, and polyethylene glycol."

Answered by AI

Clinical Trials for Septra Ds

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Septra Ds clinical trials?

We made a collection of clinical trials featuring Septra Ds, we think they might fit your search criteria.
Go to Trials

Have you considered Septra Ds clinical trials?

We made a collection of clinical trials featuring Septra Ds, we think they might fit your search criteria.
Go to Trials
Image of McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) in Montreal, Canada.

Low-Dose Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia

18 - 100
All Sexes
Montreal, Canada

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX. Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.

Phase 3
Waitlist Available

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

Emily G McDonald, MD MSc

Image of Temple University in Philadelphia, United States.

UV Water Treatment for Gastroenteritis in Children

6 - 59
All Sexes
Philadelphia, PA

Approximately 40 million people in the US are served by private, and frequently untreated, wells. Our best estimate is that 1.3 million cases of gastrointestinal illnesses (GI) per year are attributed to consuming water from untreated private wells in the US, but in reality, there are no robust epidemiological data that can be used to estimate cases of GI attributable to these sources. We propose the first randomized controlled trial (RCT) to estimate the burden of GI associated with private well water. We will test if household treatment of private well water by ultraviolet light (UV) vs. sham (inactive UV device) decreases the incidence of GI in children under 5. We will also examine the presence of viral, bacterial, and protozoan pathogens in stool and well water from participants. These data will fill a knowledge gap on sporadic GI associated with federally-unregulated private water supplies in the US.

Recruiting
Paid Trial

Temple University

Heather M Murphy, PhD

Have you considered Septra Ds clinical trials?

We made a collection of clinical trials featuring Septra Ds, we think they might fit your search criteria.
Go to Trials